Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of sonelokimab in moderate to severe hidradenitis suppurativa
NL-OMON51658Phase 2Active, not recruiting
- Sponsor
- -
- Start
- Nov 2022
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sonelokimab in hidradenitis suppurativa (HS) (4 arms). Primary endpoint: HiSCR75 at Week 12. Started Nov 2022; status: active, not recruiting.
02
Drugs
sonelokimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON51658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51658.